Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of everolimus to SAve REnal Function (SAREFU) in long term heart transplanted patients

Trial Profile

Efficacy and safety of everolimus to SAve REnal Function (SAREFU) in long term heart transplanted patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Everolimus (Primary) ; ACE inhibitors; Ciclosporin
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Acronyms SAREFU
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Apr 2013 Results at 5 years presented at the 33rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 14 Apr 2011 Three-year results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top